07:59 AM EDT, 08/28/2024 (MT Newswires) -- Krystal Biotech ( KRYS ) subsidiary Jeune Aesthetics said Wednesday that interim data from a phase 1 trial assessing its experimental aesthetic drug KB301 showed positive results.

When assessing the decollete region, the company said that 94% of subjects showed at least a one-point improvement in wrinkles at two months, with 28% achieving the maximum two-point improvement in cohort 3.

It added that when evaluating lateral canthal lines, 75% of subjects had at least a one-point improvement at two months, with 50% achieving a two-point improvement in cohort 4.

Both cohorts also reported improved skin attributes like crepiness, hydration, and radiance.